Despite decades of focused research, the field has yet to develop a prophylactic vaccine. In the RV144 vaccine trial, non-neutralizing antibody responses were identified as a correlate for prevention of HIV acquisition. However, factors that predict the development of such antibodies are not fully elucidated. We sought to define the contribution of circulating T follicular helper (cTfh) cell subsets to the development of non-neutralizing antibodies in HIV-1 clade C infection. Study participants were recruited from an acute HIV-1 clade C infection cohort. Plasma anti-gp41, -gp120, -p24 and -p17 antibodies were screened using a customized multivariate Luminex assay. Phenotypic and functional characterization of cTfh were performed using HLA class II tetramers and intracellular cytokine staining. In this study, we found that acute HIV-1 clade C infection skewed differentiation of functional cTfh subsets towards increased Tfh1 (p=0.02) and Tfh2 (p<0.0001) subsets, with a concomitant decrease in overall Tfh1-17 (that shares both Tfh1 and Tfh17 properties) (p=0.01) and Tfh17 subsets (p<0.0001) compared to HIV negative subjects. Interestingly, the frequencies of Tfh1 during acute infection (5.0-8.0 weeks post-infection) correlated negatively with set point viral load (p=0.03, r=-60) and were predictive of p24-specific plasma IgG titers at one year of infection (p=0.003, r=0.85). Taken together, our results suggest that circulating the Tfh1 subset plays an important role in the development of anti-HIV antibody responses and contributes to HIV suppression during acute HIV-1 infection. These results have implications for vaccine studies aimed at inducing long lasting anti-HIV antibody responses. Importance: The HIV epidemic in southern Africa accounts for almost half of the global HIV burden with HIV-1 clade C being the predominant strain. It is therefore important to define immune correlates of clade C HIV control that might have implications for vaccine design in this region. T follicular helper (Tfh) cells are critical for the development of HIV-specific antibody responses and could play a role in viral control. Here we showed that the early induction of circulating Tfh1 cells during acute infection correlated positively with the magnitude of p24-specific IgG and was associated with lower set point viral load. This study highlights a key Tfh cell subset that could limit HIV replication by enhancing antibody generation. This study underscores the importance of circulating Tfh cells in promoting non-neutralizing antibodies during HIV-1 infection.
Background: Broadly neutralizing antibodies (bnAbs) offer a promising alternative for HIV prevention and treatment, with the potential to cross the blood–brain barrier. However, the extent to which viral genetic variation between the peripheral blood and central nervous system impacts bnAb sensitivity remains insufficiently characterized. This study investigates sequence differences and neutralization profiles of matched plasma- and cerebrospinal fluid (CSF)-derived HIV-1 subtype C (HIV-1C) variants in patients coinfected with cryptococcal meningitis. Methods: Matched plasma and CSF samples were obtained from seven participants with HIV-cryptococcal meningitis coinfection in Durban, KwaZulu-Natal, South Africa. HIV-1C env was amplified, cloned into a vector, and sequenced by Sanger sequencing. Amino acid sequences within bnAb epitopes were compared between plasma- and CSF-derived clones. Additionally, we generated Env-pseudotyped viruses and assessed their neutralisation sensitivity using eight bnAbs targeting five known bnAb epitopes on HIV-1 Env. Results: Discordant bnAb escape mutations and variations in neutralization sensitivity between plasma and CSF were observed in the CD4 binding site, V2 Apex and the V3 glycan supersite. Despite these variations, VRC07-523LS demonstrated broad neutralisation activity, with no significant differences in sensitivity across plasma and CSF variants. However, only minor neutralization sensitivity variations were observed in the MPER and gp120-gp41 interface between plasma and CSF compartments. Conclusions: These findings highlight potential differences in amino acid signatures and neutralisation sensitivity between matched plasma- and CSF-derived HIV-1C variants. Our findings show that bnAb targeting the CD4-binding site (VRC07-523LS) maintain cross-compartment efficacy and have a potential in the clearance of viral reservoirs.
Background: HIV-1 subtype C (HIV-1C) may use multiple coreceptors to enter cells. However, the differences in coreceptor usage between HIV-1C Env variants from peripheral blood and those from the central nervous system (CNS) are still not completely understood. This study characterised the coreceptor usage of viral populations that circulate in the central nervous system (CNS) and plasma compartments to enhance understanding of HIV-1C pathogenesis and inform the appropriate use of entry inhibitors. Methods: We characterised the in vitro coreceptor usage of HIV-1C envelope protein (Env) variants circulating in peripheral blood and the cerebrospinal fluid (CSF) of twelve participants living with HIV and cryptococcal meningitis coinfection. We evaluated the coreceptor usage using Geno2pheno, Phenoseq and Web-PSSM coreceptor prediction tools, and confirmed coreceptor usage in U87 cell lines. We also analysed HIV-1 Env V3 loop characteristics for associations with CCR5 or CXCR4 usage. Results: Our findings indicated that CSF-derived clones primarily used CCR5, while plasma-derived clones varied usage between CCR5, CXCR4 and CCR3 in vitro. HIV-1 Envs with a long V3 loop (37 amino acids), absence of potential N-linked glycosylation sites (PNGS), and a high net charge (> 5 +) were associated with CXCR4 usage. Whereas shorter or standard-length V3 loops (34–35 amino acids), presence of PNGS, lower net charge (range + 2 to + 5) and a GPGQ crown motif were associated with CCR5 usage. Conclusion: Our findings reveal compartment-specific heterogeneity in HIV-1 subtype C coreceptor usage during advanced infection. CSF-derived variants were primarily limited to CCR5 usage, while plasma-derived variants exhibited broader usage of CXCR4 and alternative coreceptors. Phenotypic validation, together with distinct V3 loop signatures, provides evidence of viral adaptation to divergent tissue environments and highlights limitations of genotypic tropism prediction alone. These findings advance the understanding of HIV-1C pathogenesis and have implications for evaluating coreceptor usage in the context of entry inhibitor–based interventions particularly in regions where HIV-1C is endemic and diagnostic resources are limited.